Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H25ClN2OS.2ClH |
Molecular Weight | 473.887 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1
InChI
InChIKey=LPWNZMIBFHMYMX-MHKBYHAFSA-N
InChI=1S/C22H25ClN2OS.2ClH/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26;;/h1-2,4-8,16,26H,3,9-15H2;2*1H/b18-5-;;
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987
Curator's Comment: Description was created based on several sources, including
https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987
Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. Zuclopenthixol, a thioxanthene derivative, has high affinity for both dopamine D1 receptors and
dopamine D2 receptors. Zuclopenthixol also has high affinity for α1-adrenergic and 5-HT2
receptors. Zuclopenthixol (CLOPIXOL®) is avavilable in the form of tablets and solution for intramuscular injections.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 |
|||
Target ID: CHEMBL2056 |
|||
Target ID: CHEMBL2094251 |
|||
Target ID: CHEMBL2093870 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CLOPIXOL Approved UseZuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. |
|||
Primary | CLOPIXOL Approved UseZuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. |
PubMed
Title | Date | PubMed |
---|---|---|
Prolonged oculogyric crisis on addition of nifedipine to neuroleptic medication regime. | 1987 Jan |
|
Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. | 1991 Dec |
|
Clozapine and weight gain. | 2001 May |
|
Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder. | 2014 May 15 |
Patents
Sample Use Guides
Clopixol tablets: The usual dose is 10 to 50 mg per
day.
Clopixol Acuphase injection: The usual dose is 50 to 150 mg (1 to 3 mL) every 2 to 3 days or as
instructed by your doctor.
Clopixol Depot injection: The usual dose is 200 to 400 mg (1 to 2 mL) every second to fourth week.
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
58045-23-1
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | |||
|
DTXSID5045332
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | |||
|
C95837
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | |||
|
261-080-2
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | |||
|
m3653
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
102546
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
DBSALT000546
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | |||
|
100000085645
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | |||
|
6433208
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | |||
|
7042692VYN
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | |||
|
329015
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY | |||
|
SUB05197MIG
Created by
admin on Fri Dec 15 18:36:39 GMT 2023 , Edited by admin on Fri Dec 15 18:36:39 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD